Physician profile

Christopher Farrell

Neurological Surgery · Philadelphia, PA

NPI 1922134394

$10,120.62

in general payments reported to CMS, 2019-2025

7 companies · $13.84 in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$9,377.95
Food and Beverage$220.27
Travel and Lodging$154.90

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ethicon INC. $9,420.73 2023-2024
Medtronic, INC. $250.12 2022
Genzyme Corporation $133.08 2024
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $117.38 2019-2020
Medical Device Business Services, INC. $112.12 2024 Matrixneuro
Depuy Synthes Sales INC. $73.35 2023-2024 Synthecel, Matrixneuro
Supreme Orthopedic Systems, LLC $13.84 2025

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Christopher Farrell

$10,120.62

in general payments reported 2019-2025

Years
2019-2025
Top company
Ethicon INC.

https://glasscript.com/doctor/418105/christopher-farrell

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.